Company: SMNR
Filing Date: 2025-12-03
Form Type: S-8
Source: 0001193125-25-306962
Chunk: 17

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-12-03
Form: S-8
Chunk 17
---
’s payroll cycle and the Company shall pay COBRA premiums for Mr. Ma and his covered
dependents for a period of up to 12 months, subject in each case to such Mr. Ma executing a release in favor of the Company. Additionally, Mr. Ma’s outstanding and vested stock options as of the date of his termination will remain
exercisable for 24 months post-termination. His Employment Agreement also provides that if there is a Change in Control more than 6 months after the effective date of the Business Combination and prior to the date on which Mr. Ma’s
employment with the Company terminates (as each term is defined in his Employment Agreement), Mr. Ma will receive a lump-sum payment equal to (i) two times the sum of his base salary and target
annual bonus, plus (ii) $3,000 multiplied by 24, in respect of an estimate of benefit premiums for such executive officer. Additionally, outstanding and unvested equity awards with solely time-based vesting shall vest in full and any
performance-based vesting requirement shall be deemed satisfied and will become vested in full upon a Change in Control and Mr. Ma’s outstanding and vested stock options will remain exercisable for 24 months post-termination.

2025 Equity Grants for Directors and Executive Officers

Our 2025 Equity Incentive Plan (the “2025 EIP”) is subject to the approval of our stockholders and upon receipt of such approval,
the 2025 EIP will become effective and the Company may grant awards thereunder. Following the effectiveness of the 2025 EIP, our directors are expected to receive the following grants of stock option awards, which will vest in 48 equal monthly
installments following the grant date thereof.

10

| Name and Position                 |     | Number of Shares 
          Subject 
               to 
      Anticipated 
        Awards(1) |
| Jay Chun, M.D., Ph.D., Director   |     |          250,000 |
| Dorman Followwill, Director       |     |          250,000 |
| Yue Alexander Wu, Ph.D., Director |     |          250,000 |

| (1) | The grants are subject to, among other things, approval by our Board of such grants following the effectiveness                                                                                                 
 of a Registration Statement on Form S-8 expected to be filed by Semnur with respect to the 2025 EIP, the effectiveness of the 2025 EIP and the continued service